THE EFFECTIVENESS OF POLY-HERBAL ADJUVANTS FOR THE STANDARD TREATMENT OF COVID 19 IN PATIENTS WITHMODERATE DEGREE
European Journal of Molecular & Clinical Medicine,
2021, Volume 8, Issue 3, Pages 2945-2957
AbstractThis study aims to examine the effectiveness of polyherbal (ONOIWA MX) containing5100mg Channa striata extract, Curcuma xanthorriza 240mg and Moringa oleifera 240mg asadjuvantsforstandard treatmentof Covid 19in themanagementof moderate pneumonia.
This is a clinical randomized controlled single blind parallel study conducted during the COVID-19 pandemic on patients having symptoms as well as positive cases, meanwhile, patients werefollow-up for 7 days after the last dose of Onoiwa MX. A total of 48 patients were COVID-19positive and divided into 2 groups namely group I (n = 24) given standard therapy 2x200 mghydrochloroquine, 1x 500 mg azithromycin injection, 2x75 mg oseltamivir as well as750 mgLevofloxacininjectionandOnoiwaMX3x1sacchetfor7days.Meanwhile,patientsinthesecondgroupweregiven2x200 mghydrochloroquin,1x500mgazithromycin,2x75 mgoseltamiviraswellas750 mgLevofloxacininjection+control(placebo)sacchet3timesadayfor7days.Furthermore,a clinicalandvitalsigns examinationswerecarriedoutonthepatientdaily.
The administration of ONOIWA MX capsules as an adjuvant therapy for standard COVID-19treatmentreduceparameters suchas D-dimer, CRPand clinical symptoms.
- Article View: 7
- PDF Download: 11